Department of Gastroenterology, Adelaide & Meath Hospital, Tallaght, Dublin 24, Republic of Ireland.
Ir J Med Sci. 2010 Dec;179(4):597-8. doi: 10.1007/s11845-008-0238-8. Epub 2008 Oct 24.
Infliximab, a monoclonal chimeric antibody to tumour necrosis factor (TNF)α, is a novel therapy used in the management of chronic refractory pouchitis that is unresponsive to conventional medical therapy.
This report describes a case of non-infective bursitis following infliximab therapy and documents the role of musculoskeletal ultrasound in detecting soft tissue fluid collections and in guiding aspiration.
A high index of suspicion is required when assessing new or worsening musculoskeletal pain in patients receiving infliximab and involvement of a rheumatologist at an early stage is essential in order to appropriately diagnose and manage this condition.
英夫利昔单抗是一种针对肿瘤坏死因子（TNF）α的单克隆嵌合抗体，是一种用于治疗慢性难治性袋炎的新型疗法，对于常规药物治疗无效的袋炎患者有效。
本报告描述了一例英夫利昔单抗治疗后发生的非感染性滑囊炎病例，并记录了肌肉骨骼超声在检测软组织积液和引导抽吸中的作用。
在评估接受英夫利昔单抗治疗的患者新发或加重的肌肉骨骼疼痛时，需要高度怀疑这种情况，并且早期请风湿病专家参与对于正确诊断和管理这种情况至关重要。
